Renalytix shares fall 25% as revenues miss expectations

Renalytix shares fall 25% as revenues miss expectations Proactive uses images sourced from Shutterstock Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) shares dropped 25% to 4.25p after the company posted first-half revenues of $1.6 million and flagged slower-than-expected progress in rolling out its kidney disease diagnostic test. The company, which develops the FDA-approved and Medicare-reimbursed kidneyintelX.dkd test for early-stage diabetic kidney disease, said full-year revenue is now expected to reach ...